# US Single Use Bioprocessing Market > US Single-Use Bioprocessing Market Research Report By Product (Filtration Assemblies, Disposable Bioreactors, Disposable Mixers, Media Bags and Containers, Others), By Application (Filtration, Purification, Cell Culture, Others), By End-User (Biopharmaceutical Manufacturers, Clinical & Academic Research Institutes, Others) and By Workflow (Upstream, Fermentation, Downstream) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 20.81% - **2024:** $ 2,400 Million - **2025:** $ 2,899.44 Million - **2035:** $ 19,200 Million - **Key Players:** Thermo Fisher Scientific (US), Sartorius AG (DE), Merck KGaA (DE), GE Healthcare (GB), Danaher Corporation (US), Eppendorf AG (DE), Pall Corporation (US), Fujifilm Diosynth Biotechnologies (GB) **Report ID:** MRFR/HC/13150-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-single-use-bioprocessing-market-14677 --- ## Market Summary ## **US Single-Use Bioprocessing Market Overview** As per MRFR analysis, the US Single-Use Bioprocessing Market Size was estimated at 3.47 (USD Billion) in 2023. The US Single-Use Bioprocessing Market Industry is expected to grow from 4.19 (USD Billion) in 2024 to 9.1 (USD Billion) by 2035. The US Single-Use Bioprocessing Market CAGR (growth rate) is expected to be around 7.294% during the forecast period (2025 - 2035). ### **Key US Single-Use Bioprocessing Market Trends Highlighted** The US Single-Use Bioprocessing Market is significantly influenced by several key market drivers. The increasing demand for biopharmaceuticals has fueled the need for efficient production methods, making single-use technologies attractive due to their flexibility and reduced operational costs. The US government has been supportive of bioprocess innovation, promoting initiatives that encourage the adoption of advanced manufacturing technologies. This has led to a surge in investments and research dedicated to enhancing single-use systems and addressing regulatory requirements. Moreover, the ongoing shift towards personalized medicine in the US further drives the demand for single-use bioprocessing, as these systems are more adaptable to smaller-scale production runs.In recent times, there are numerous opportunities to be explored within the US Single-Use Bioprocessing Market. Companies are focusing on integrating digital technologies and automation to further optimize single-use processes. The growing interest in cell and gene therapies in the US presents a lucrative opportunity, as single-use systems can provide the desired flexibility for the production of these complex therapies. The emergence of collaboration between biopharma companies and technology providers can also result in innovative solutions that enhance efficiency and safety in production. Trends in the US market reflect an increasing emphasis on sustainability and reducing environmental impact.Manufacturers are actively seeking eco-friendly materials for single-use products, aligning with the broader environmental goals set forth by federal and state regulations. Additionally, there is a rising trend towards the use of modular and hybrid systems, which allow for greater scalability. This evolution in the market indicates a move towards a more integrated and user-centered approach in bioprocessing, ensuring that the US maintains its leadership in biopharmaceutical production innovation. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Single-Use Bioprocessing Market Drivers** ### **Rising Demand for Biopharmaceuticals** The US is experiencing a significant growth in the biopharmaceutical sector, driven by an increase in chronic diseases and aging population. According to the Centers for Disease Control and Prevention (CDC), around 60% of adults in the US have a chronic disease, and 40% have two or more. This rising prevalence is prompting pharmaceutical companies to invest more in the development of biopharmaceutical products. Companies like Amgen and Genentech are expanding their production capabilities with single-use bioprocessing technologies to meet this demand. The flexibility and efficiency provided by single-use systems enable faster turnaround times for biopharmaceutical production, catering to an ever-increasing patient population that requires specialized treatments. The US Single-Use Bioprocessing Market Industry is thus poised for accelerated growth, as established organizations leverage these technologies to improve their production pipelines. ### **Technological Advancements in Bioprocessing** The integration of advanced technologies in bioprocessing is a major driver for the US Single-Use Bioprocessing Market. The introduction of automation and digitalization in processes has made biomanufacturing more efficient and reliable. For instance, the US Food and Drug Administration (FDA) has reported that more than 70% of biotechnology firms are adopting single-use systems due to their ease of use and reduced cross-contamination risks. Major players like Thermo Fisher Scientific and Sartorius are leading the charge in developing innovative single-use products that enhance productivity and ensure compliance with stringent regulatory standards. The focus on innovation, supported by substantial Research and Development investments, is critical to the growth of the US Single-Use Bioprocessing Market Industry. ### **Increased Focus on Cost-Effective Solutions** In the US, the bioprocessing industry is increasingly turning towards cost-effective solutions to maintain profitability. Single-use bioprocessing systems significantly reduce capital investment and operational costs associated with cleaning and sterilization of conventional systems. According to the BioProcess International magazine, switching to single-use technology can lower costs by up to 30% per unit operation, which is especially crucial for small to medium-sized enterprises. Companies such as Merck and Pfizer actively implement single-use manufacturing strategies to optimize their operations, reflecting a broader market trend towards efficiency and sustainability. The cost advantages of single-use systems are a key growth factor driving the US Single-Use Bioprocessing Market Industry. ## **US Single-Use Bioprocessing Market Segment Insights** ### **Single-Use Bioprocessing Market Product Insights** The US Single-Use Bioprocessing Market reflects a significant shift towards more efficient, flexible, and cost-effective biomanufacturing solutions. With innovations driving the development of single-use technologies, the market features various key products that serve essential roles in bioprocessing applications. Filtration Assemblies play a crucial role in maintaining product integrity and ensuring sterility during bioprocessing, significantly impacting yield and quality. Disposable Bioreactors represent a prominent trend in the industry, as they facilitate bioproduction without the need for extensive cleaning and validation, thereby enhancing operational efficiency.Alongside these, Disposable Mixers are gaining traction due to their ability to ensure homogeneity in fluid mixing processes, a critical aspect in upstream and downstream processing. Media Bags and Containers serve as vital components for storing and transporting cell culture media and other solutions, underscoring the demand for containers that minimize contamination risks while ensuring easy accessibility. The diverse applications of these products showcase their importance in the bioprocessing landscape, often catering to the growing needs of the pharmaceutical and biotechnology sectors.As the US Single-Use Bioprocessing Market continues to expand, these products are expected to adapt to meet stringent regulatory requirements and achieve operational excellence, thereby capturing a critical portion of the market share in years to come. Overall, the segmentation of products plays a pivotal role in supporting the flexibility and scalability that modern bioprocessing requires, ultimately driving innovation and growth within the industry. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Single-Use Bioprocessing Market Application Insights** The Application segment of the US [Single-Use Bioprocessing](../../../reports/single-use-bioprocessing-market-12332) Market plays a pivotal role in addressing the growing demands of the biopharmaceutical industry. This segment encompasses various functionalities including Filtration, Purification, Cell Culture, and others, each contributing uniquely to the bioprocessing landscape. Filtration processes significantly enhance product safety and quality in the manufacturing of biopharmaceuticals, while Purification techniques are crucial for isolating and refining biologics, thus ensuring the efficacy of therapeutic agents. Cell Culture applications are vital as they support the production of vaccines and monoclonal antibodies, reflecting a robust demand triggered by advancements in personalized medicine and biologic therapies. Additionally, other applications continue to innovate, catering to specific customer requirements, driven by technological advancements and regulatory changes. The increasing adoption of single-use technologies, coupled with the need for cost-effective and efficient biomanufacturing solutions, underscores the growth potential within the US Single-Use Bioprocessing Market. Overall, the dynamics within this segment highlight a progressive trend towards scalable and adaptable bioprocessing methodologies, aligning with the industry's direction towards sustainability and enhanced productivity. ### **Single-Use Bioprocessing Market End-User Insights** The End-User segment of the US Single-Use Bioprocessing Market plays a crucial role in driving the industry forward, with Biopharmaceutical Manufacturers being a dominant force due to their extensive reliance on efficient and cost-effective bioprocessing solutions. These manufacturers increasingly adopt single-use technologies to streamline production processes, minimize contamination risks, and reduce overall operational costs. Clinical and Academic Research Institutes also significantly contribute to market dynamics, utilizing innovative bioprocessing techniques as they pursue groundbreaking research and drug development initiatives. The demand for flexibility and scalability in manufacturing processes leads to an emphasis on single-use systems, allowing these institutions to operate with enhanced efficiency and reduced turnaround times. Additionally, a range of other users, spanning various sectors, further enriches the market landscape by diversifying applications and fostering innovation within the industry. This increased variety enhances the overall adaptability and responsiveness of the US Single-Use Bioprocessing Market as it evolves to meet the specific needs of different End-User groups. As these users continue to prioritize advancements in bioprocessing, the market is expected to witness sustained growth, reflecting a broader trend toward modernization and technological adoption across the biopharmaceutical space. ### **Single-Use Bioprocessing Market Workflow Insights** The US Single-Use Bioprocessing Market, particularly the Workflow segment, is experiencing noteworthy growth driven by various technological advancements and increasing demand for biologics. The Workflow segment encompasses essential processes such as Upstream, Fermentation, and Downstream, each playing a vital role in bioprocessing efficiency. Upstream processes focus on cell culture and the initial stages of production, ensuring high cellular yield, which is critical for the efficacy of biologics. Fermentation, a crucial element, transforms substrates into desired products, highlighting its importance in meeting the rising demand for therapeutics. Downstream processes emphasize the purification and formulation of products, ensuring quality and compliance with regulatory standards, which is significant in the highly regulated US market. The trend toward automation and integration within the Workflow segment is enhancing productivity and reducing operational costs. There's also a growing emphasis on sustainability and cost-efficiency, which drives the adoption of single-use technologies. As biopharmaceutical companies continuously seek innovative solutions to enhance their production capabilities, the Workflow segment stands out as a cornerstone of operational excellence within the US Single-Use Bioprocessing Market, offering substantial opportunities for growth and development. ## **US Single-Use Bioprocessing Market Key Players and Competitive Insights** The US Single-Use Bioprocessing Market is characterized by dynamic competition among key players focusing on the development and advancement of bioprocessing technologies tailored for the biopharmaceutical industry. The competitive landscape features a mix of established global corporations and emerging companies that aim to enhance operational efficiency, reduce contamination risks, and provide flexible solutions for pharmaceutical manufacturing. This market has seen significant growth due to an increased demand for biologics, advanced therapies, and streamlined production processes. As a result, companies are investing in innovation, forming strategic partnerships, and expanding their product portfolios to gain a competitive edge in this rapidly evolving environment. Market leaders are continuously seeking ways to enhance their offerings and drive operational excellence, which is shaping the future of bioprocessing technology in the United States. Danaher Corporation holds a significant position in the US Single-Use Bioprocessing Market, where it leverages its diverse portfolio of technologies to provide robust bioprocessing solutions. The company's strengths lie in its commitment to innovation, quality assurance, and customer support, allowing it to meet the stringent demands of the biopharmaceutical sector. Danaher’s extensive range of single-use products is designed to enhance efficiency and minimize the risks associated with traditional bioprocessing methods. The company's clear focus on R&D continues to yield advanced solutions that are central to the production of monoclonal antibodies and other biologics. Danaher Corporation also enjoys a strong market presence owing to its reputation for reliability and excellence, facilitating partnerships with key industry stakeholders and fostering a collaborative approach to bioprocessing challenges. Lonza Group is another prominent player in the US Single-Use Bioprocessing Market, with a well-established reputation for its high-quality contract manufacturing services and product offerings. The company provides a comprehensive range of single-use bioprocessing solutions, including bioreactors, cell culture bags, and filtration devices. Lonza's strengths lie in its extensive experience, innovative product line, and commitment to enhancing bioprocessing efficiency for its clients. The company has engaged in significant mergers and acquisitions to expand its capabilities and strengthen its position in the market. Through these strategic movements, Lonza has broadened its service offering, making it a preferred choice for companies seeking reliable biopharmaceutical manufacturing solutions. By integrating advanced technologies and maintaining high-quality standards, Lonza Group effectively addresses the evolving needs of the bioprocessing landscape in the United States, thereby maintaining a forward-thinking approach in this competitive sector. ## **Key Companies in the US Single-Use Bioprocessing Market Include** ## **US Single-Use Bioprocessing Market Industry Developments** In the US Single-Use Bioprocessing Market, recent developments have showcased significant growth and investment activities. Leading companies like Danaher Corporation and Thermo Fisher Scientific have expanded their product portfolios and enhanced their manufacturing capabilities to meet the growing demand for single-use technologies in bioprocessing. Particularly in August 2023, AbbVie announced the establishment of a new facility focusing on single-use systems, signaling a strong commitment to advancing bioprocessing technologies. Additionally, Merck KGaA has invested heavily in research to optimize the use of single-use bioreactors, reinforcing its position in the market. Notable merger activities include Baxter International's acquisition of a bioprocessing company in July 2023, aimed at consolidating its presence in the single-use segment. The market valuation for companies like Repligen Corporation has seen a significant increase due to heightened demand as regulators emphasize more flexible and efficient manufacturing methods. Eppendorf AG reported substantial revenue growth in recent quarters, reflecting the robust market dynamics. The push towards sustainable practices, such as recycling single-use components, is also shaping industry trends as companies look to meet regulatory and environmental standards. ## **US Single-Use Bioprocessing Market Segmentation Insights** ### **Single-Use Bioprocessing Market Product Outlook** ### **Single-Use Bioprocessing Market Application Outlook** ### **Single-Use Bioprocessing Market End-User Outlook** ### **Single-Use Bioprocessing Market Workflow Outlook** ## Market Drivers ### Rising Demand for Biopharmaceuticals The increasing demand for biopharmaceuticals is a primary driver of the single use-bioprocessing market. As the biopharmaceutical sector continues to expand, the need for efficient and flexible manufacturing processes becomes paramount. The market for biopharmaceuticals in the US is projected to reach approximately $300 billion by 2025, indicating a robust growth trajectory. This surge necessitates the adoption of single use technologies, which offer advantages such as reduced contamination risks and lower operational costs. The single use-bioprocessing market is thus positioned to benefit significantly from this trend, as manufacturers seek to streamline production and enhance product quality. Furthermore, the ability to quickly adapt to changing market demands makes single use systems particularly appealing to biopharmaceutical companies aiming to maintain a competitive edge. ### Growing Interest in Personalized Medicine The growing interest in personalized medicine is emerging as a key driver for the single use-bioprocessing market. As the healthcare landscape shifts towards tailored therapies, the demand for flexible and adaptable manufacturing processes increases. Single use systems offer the agility required to produce small batches of customized biopharmaceuticals efficiently. The single use-bioprocessing market is well-positioned to support this trend, as it allows for rapid adjustments in production to meet specific patient needs. With the personalized medicine market projected to reach $2.4 trillion by 2025, the implications for single use technologies are substantial. This growth indicates a potential for increased adoption of single use systems, as manufacturers seek to align their capabilities with the evolving demands of personalized healthcare. ### Increased Focus on Quality and Compliance The emphasis on quality and compliance within the biopharmaceutical industry is a significant driver of the single use-bioprocessing market. Regulatory bodies in the US are increasingly mandating stringent quality standards for biopharmaceutical products, necessitating the adoption of reliable and compliant manufacturing processes. Single use systems are designed to minimize contamination risks, thereby enhancing product safety and quality. The single use-bioprocessing market is adapting to these regulatory requirements by providing solutions that meet or exceed compliance standards. As companies strive to maintain their market position, the integration of single use technologies becomes essential for ensuring adherence to quality regulations. This focus on compliance is likely to propel market growth, as organizations prioritize investments in systems that support regulatory adherence. ### Cost Efficiency and Operational Flexibility Cost efficiency and operational flexibility are pivotal factors driving the single use-bioprocessing market. Single use systems significantly reduce the need for cleaning and validation processes, leading to lower operational costs and shorter production timelines. This is particularly beneficial for small to medium-sized enterprises that may lack the resources for extensive cleaning protocols. The single use-bioprocessing market allows for rapid scale-up and scale-down capabilities, enabling manufacturers to respond swiftly to market fluctuations. As a result, companies can optimize their production strategies without incurring substantial capital expenditures. The potential for cost savings is estimated to be around 30% compared to traditional bioprocessing methods, making single use technologies an attractive option for many organizations in the biopharmaceutical sector. ### Technological Advancements in Bioprocessing Technological advancements play a crucial role in shaping the single use-bioprocessing market. Innovations in materials and design have led to the development of more efficient single use systems, which are increasingly being integrated into bioprocessing workflows. For instance, the introduction of advanced filtration and mixing technologies has improved the performance of single use components, thereby enhancing overall process efficiency. The single use-bioprocessing market is witnessing a shift towards automation and digitalization, which further streamlines operations and reduces human error. As companies invest in these technologies, the market is expected to grow, with estimates suggesting a compound annual growth rate (CAGR) of around 15% over the next few years. This trend indicates a strong inclination towards adopting cutting-edge solutions in bioprocessing. ## Future Outlook The [Single Use Bioprocessing Market](https://www.marketresearchfuture.com/reports/single-use-bioprocessing-market-12332) is projected to grow at a 20.81% CAGR from 2025 to 2035, driven by technological advancements and increasing demand for biopharmaceuticals. **New opportunities:** - Development of integrated single-use systems for enhanced efficiency. Expansion into emerging markets with tailored bioprocessing solutions. Investment in sustainable materials for single-use products to meet regulatory demands. By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic investments. ## Segment Insights ### By Product: Filtration Assemblies (Largest) vs. Disposable Bioreactors (Fastest-Growing) In the US single use-bioprocessing market, the product segment is primarily dominated by Filtration Assemblies, which hold the largest market share among other product categories. Disposable Bioreactors and Disposable Mixers follow, contributing significantly to the overall market. However, Media Bags & Containers, while essential, make up a smaller portion of the market share, illustrating the differentiation in consumer preferences towards filtration and bioreactor technologies. Notably, Disposable Bioreactors are emerging as the fastest-growing product in the segment, driven by advancements in biomanufacturing techniques and the rising demand for flexible production solutions. This growth is supported by innovations in disposable technologies that enhance process efficiency and reduce contamination risks. As biopharmaceutical manufacturing evolves, the continuous need for scalable and efficient solutions will likely propel the growth of this segment further. Filtration Assemblies (Dominant) vs. Disposable Bioreactors (Emerging) Filtration Assemblies are considered the dominant player in the US single use-bioprocessing market due to their established effectiveness in removing impurities and ensuring high-purity output in biologics processing. Their design flexibility and compatibility with various bioprocessing needs make them a preferred choice among manufacturers. On the other hand, Disposable Bioreactors are rapidly emerging, characterized by their ability to offer scalable solutions that align with the growing demand for personalized medicine. These bioreactors allow for efficient cell culture operations without the extensive cleaning and validation requirements of reusable systems, making them increasingly popular in biopharmaceutical production. ### By Application: Filtration (Largest) vs. Purification (Fastest-Growing) In the US single use-bioprocessing market, the application segment demonstrates a diverse distribution of market share. Filtration holds the largest share, benefiting from its critical role in removing impurities and ensuring product quality throughout various bioprocessing stages. Meanwhile, purification technologies are gaining traction, allowing biopharmaceutical manufacturers to meet stringent quality standards more effectively, hence contributing to segment growth. Growth trends within this segment are driven by the increasing demand for biopharmaceuticals and cell therapies, which require efficient bioprocessing solutions. Innovations in filtration and purification techniques, such as advanced membrane technologies, are enhancing operational efficiency and reducing costs. Additionally, the trend towards single use systems is aligning with regulatory requirements, promoting faster implementation in production facilities, thus attracting investments and fostering market expansion. Filtration (Dominant) vs. Cell Culture (Emerging) Filtration has established itself as the dominant application in the market, widely employed for clarification and concentration of [biological](../../../reports/cancer-biologic-therapy-market-566) products. Its robustness and efficiency in various phases of bioprocessing is unmatched, enabling manufacturers to maintain high quality and yield. On the other hand, cell culture is recognized as an emerging area with growing applications in producing biopharmaceuticals and vaccines. The shift towards more complex biologics increases the reliance on efficient cell culture technologies, positioning it for rapid growth. Innovations such as automated cell culture systems and optimized media are further enhancing productivity in this segment, catering to the rising demands of modern biotechnology. ### By End User: Biopharmaceutical Manufacturers (Largest) vs. Clinical & Academic Research Institutes (Fastest-Growing) The US single use-bioprocessing market shows a varied distribution among its end user segments, with Biopharmaceutical Manufacturers commanding the largest share. This segment is pivotal in driving the demand for single use solutions, leveraging their established infrastructure and extensive R&D capabilities. In contrast, Clinical & Academic Research Institutes play a significant role, albeit smaller in share, focusing on innovative research and development projects. Growth trends in the US single use-bioprocessing market are heavily influenced by the increasing adoption of biopharmaceutical manufacturing techniques. The biopharmaceutical sector is rapidly expanding, with a growing number of biologics being developed and a push towards more personalized medicine. Clinical & Academic Research Institutes are emerging as the fastest-growing segment, driven by a surge in funding and collaborations aimed at pioneering new therapies and technologies. Biopharmaceutical Manufacturers (Dominant) vs. Clinical & Academic Research Institutes (Emerging) Biopharmaceutical Manufacturers serve as the dominant force in the US single use-bioprocessing market, characterized by large-scale production and a strong focus on innovation to meet regulatory standards. Their established networks facilitate efficient distribution and access to cutting-edge bioprocessing technologies. On the other hand, Clinical & Academic Research Institutes represent an emerging segment, showing dynamic growth fueled by increasing research initiatives and partnerships with biopharmaceutical companies. They are often at the forefront of developing novel therapies, utilizing single use systems to enhance their research capabilities while minimizing contamination risks and operational complexities. ### By Workflow: Upstream (Largest) vs. Downstream (Fastest-Growing) In the US single use-bioprocessing market, the distribution of market share among the workflow segments reveals that Upstream holds a substantial portion, significantly outpacing its counterparts. This dominance is driven by the increasing demand for innovative biopharmaceutical products and advances in upstream processes, which facilitate the efficient production of biological materials. Meanwhile, Downstream is gaining traction, showcasing rapid expansion attributed to the rising necessity for purification and separation processes within the bioprocessing industry. The growth trends in these segments are shaped by various factors, particularly technological advancements and market needs. Upstream processes are increasingly optimized for higher yields and better product quality, leading to greater investment in these areas. Conversely, the Downstream segment is recognized for its agility in adapting to new purification technologies, contributing to its status as the fastest-growing category. This growth is also fueled by the heightened focus on regulatory compliance and the demand for more efficient processes to meet stringent quality standards. Workflow: Upstream (Dominant) vs. Downstream (Emerging) The Upstream workflow segment is characterized by its crucial role in the initial stages of bioprocessing, where cell cultures and biological materials are produced. This segment is marked by continued investment in research and development, leading to innovations that enhance productivity and decrease time to market. The prevalent use of single-use technologies has transformed the Upstream processes, providing flexibility and reducing contamination risks. On the other hand, the Downstream segment, while historically slower, has emerged as a significant player as the demand for effective purification techniques escalates. Downstream operations focus on refining the product by removing impurities, and the integration of advanced filtration and chromatography technologies is reshaping the landscape, positioning it as an essential part of the bioprocessing workflow. ## Competitive Benchmarking The single use-bioprocessing market is characterized by a dynamic competitive landscape, driven by the increasing demand for biopharmaceuticals and the need for cost-effective manufacturing solutions. Key players such as Thermo Fisher Scientific (US), Sartorius AG (DE), and Merck KGaA (DE) are strategically positioned to leverage innovation and operational efficiency. Thermo Fisher Scientific (US) focuses on enhancing its product portfolio through continuous innovation, while Sartorius AG (DE) emphasizes strategic partnerships to expand its market reach. Merck KGaA (DE) is actively pursuing mergers and acquisitions to bolster its capabilities in bioprocessing technologies. Collectively, these strategies contribute to a competitive environment that is increasingly focused on technological advancement and operational excellence. In terms of business tactics, companies are localizing manufacturing to reduce lead times and optimize supply chains. The market structure appears moderately fragmented, with several key players exerting significant influence. This fragmentation allows for a diverse range of offerings, yet the collective strength of major companies shapes market dynamics, fostering competition that drives innovation and efficiency. In October 2025, Thermo Fisher Scientific (US) announced the launch of a new line of single-use bioreactors designed to enhance scalability and reduce production costs. This strategic move is likely to strengthen its position in the market by addressing the growing demand for flexible manufacturing solutions. The introduction of these bioreactors may also facilitate faster product development cycles for biopharmaceutical companies, thereby enhancing customer satisfaction and loyalty. In September 2025, Sartorius AG (DE) entered into a strategic partnership with a leading biotechnology firm to co-develop advanced single-use technologies. This collaboration is expected to accelerate innovation in bioprocessing, allowing Sartorius to leverage its partner's expertise in cell culture and process optimization. Such partnerships are indicative of a broader trend towards collaborative innovation, which may redefine competitive advantages in the market. In August 2025, Merck KGaA (DE) completed the acquisition of a prominent bioprocessing technology company, significantly expanding its capabilities in single-use systems. This acquisition is anticipated to enhance Merck's product offerings and market presence, positioning it as a formidable competitor in the bioprocessing landscape. The integration of new technologies and expertise could lead to improved operational efficiencies and a broader customer base. As of November 2025, current competitive trends in the single use-bioprocessing market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) into manufacturing processes. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise for enhanced innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological innovation, supply chain reliability, and sustainability initiatives. This shift underscores the importance of adaptability and forward-thinking strategies in maintaining a competitive edge. ## Recent News & Developments In the US Single-Use Bioprocessing Market, recent developments have showcased significant growth and investment activities. Leading companies like Danaher Corporation and Thermo Fisher Scientific have expanded their product portfolios and enhanced their manufacturing capabilities to meet the growing demand for single-use technologies in bioprocessing. Particularly in August 2023, AbbVie announced the establishment of a new facility focusing on single-use systems, signaling a strong commitment to advancing bioprocessing technologies. Additionally, Merck KGaA has invested heavily in research to optimize the use of single-use bioreactors, reinforcing its position in the market. Notable merger activities include Baxter International's acquisition of a bioprocessing company in July 2023, aimed at consolidating its presence in the single-use segment. The market valuation for companies like Repligen Corporation has seen a significant increase due to heightened demand as regulators emphasize more flexible and efficient manufacturing methods. Eppendorf AG reported substantial revenue growth in recent quarters, reflecting the robust market dynamics. The push towards sustainable practices, such as recycling single-use components, is also shaping industry trends as companies look to meet regulatory and environmental standards. ## Report Scope | MARKET SIZE 2024 | 2400.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 2899.44(USD Million) | | MARKET SIZE 2035 | 19200.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 20.81% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Thermo Fisher Scientific (US), Sartorius AG (DE), Merck KGaA (DE), GE Healthcare (GB), Danaher Corporation (US), Eppendorf AG (DE), Pall Corporation (US), Fujifilm Diosynth Biotechnologies (GB) | | Segments Covered | Product, Application, End User, Workflow | | Key Market Opportunities | Advancements in automation and digitalization enhance efficiency in the single use-bioprocessing market. | | Key Market Dynamics | Rising demand for flexible manufacturing solutions drives innovation in single use-bioprocessing technologies and applications. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current valuation of the US single use-bioprocessing market?** A: The market valuation was $2400.0 Million in 2024. **Q: What is the projected market size for the US single use-bioprocessing market by 2035?** A: The projected valuation for 2035 is $19200.0 Million. **Q: What is the expected CAGR for the US single use-bioprocessing market during the forecast period 2025 - 2035?** A: The expected CAGR is 20.81% during the forecast period. **Q: Which product segment holds the highest valuation in the US single use-bioprocessing market?** A: The Media Bags & Containers segment had a valuation of $6400.0 Million in 2024. **Q: What are the key applications driving the US single use-bioprocessing market?** A: The Cell Culture application had a valuation of $7680.0 Million in 2024. **Q: Who are the leading companies in the US single use-bioprocessing market?** A: Key players include Thermo Fisher Scientific, Sartorius AG, and Merck KGaA. **Q: What is the valuation of the Disposable Bioreactors segment in the US single use-bioprocessing market?** A: The Disposable Bioreactors segment was valued at $4800.0 Million in 2024. **Q: Which end user segment contributed the most to the US single use-bioprocessing market?** A: The Biopharmaceutical Manufacturers segment contributed $9600.0 Million in 2024. **Q: What is the valuation of the Downstream workflow segment in the US single use-bioprocessing market?** A: The Downstream workflow segment was valued at $7200.0 Million in 2024. **Q: What is the expected growth trend for the US single use-bioprocessing market in the coming years?** A: The market is likely to experience robust growth, reaching $19200.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-single-use-bioprocessing-market-14677*